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The fetoplacental circulation plays a key role in both short- and long-term outcomes, 
and aberrant flow indices as manifested by abnormal fetal Doppler velocimetry within 
this compartment have been associated with significant adverse consequences. These 
include fetal growth restriction, which often coexists with preeclampsia, and long-lasting 
medical issues as a result of both the underlying pathology and prematurity such as 
bronchopulmonary dysplasia, chronic lung disease, and neurodevelopmental delay. 
Furthermore, it is also clear that exposure to an abnormal in utero environment increases 
risk for long-term, adulthood issues such as cardiovascular disease. Endothelial pro-
genitor cells (EPCs) have been implicated in vasculogenesis and angiogenesis, and they 
have been isolated from both human placenta and umbilical cord blood. This review 
outlines the extensive nomenclature of EPCs, summarizes existing literature surrounding 
human placental and umbilical cord blood EPCs, explores their potential role in preg-
nancy complications and adverse perinatal outcome, and highlights key areas where 
future investigations are needed.
Keywords: endothelial progenitor cells, umbilical cord blood, placenta, endothelial colony-forming cells, 
circulating progenitor cells
iNTRODUCTiON
Of the three main components that shape placental function—the maternal uteroplacental circula-
tion, placental trophoblast, and fetoplacental blood flow—it is the fetoplacental circulation that has 
been clinically demonstrated to be most highly related to adverse perintal outcome. For instance, 
pregnancies complicated by fetal growth restriction (FGR) with abnormal fetal Doppler velocime-
try (e.g., umbilical arteries, middle cerebral artery with concern for “brain-sparing,” and ductus 
venosus) are at significantly elevated risks for stillbirth and neonatal death (1, 2). Survivors are at 
higher risk for chronic medical problems and neurodevelopmental delay (1, 2). Furthermore, even 
if a growth-restricted fetus emerges from the perinatal and early childhood periods without adverse 
consequences, multiple lines of evidence suggest that they remain at increased risk for long-term, 
adulthood issues such as cardiovascular disease (3–5).
From a structural perspective, scanning electron microscopy, stereological analysis, and math-
ematical modeling suggest that FGR placentas demonstrate impaired placental vascular angiogenesis 
(6–8). Although this is just one condition in which the fetoplacental vasculature is impaired, it 
highlights the importance of this compartment in pregnancy and long-term outcome.
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Recently, there has been substantial focus on endothelial 
progenitor cells (EPCs) and their role in vasculogenesis, angio-
genesis, and even re-endothelialization of injured vessels. This 
field continues to evolve in many areas including nomenclature, 
methods of isolation and culture, and mechanistic roles during 
pathogenesis. EPCs have been isolated from the human placenta 
and umbilical cord blood, and in comparison to those derived 
from adult peripheral blood mononuclear cells (PBMNCs), 
demonstrate unique features such as enhanced proliferative and 
clonogenic potential. This suggests that placental and/or cord 
blood EPCs might play a role in development of the fetoplacental 
vasculature, and thus, may be potential targets for treatment 
modalities aimed at improving pregnancy, fetal, neonatal, and 
long-term outcomes.
ePC HiSTORY
The initial discovery of a population of putative EPCs from 
adult peripheral blood in the late 1990s (9) changed two widely 
accepted paradigms. First, it challenged the existing notion 
that vasculogenesis occurs only during fetal development. 
Second, it disputed the concept that angiogenesis in adults 
is only able to arise through extension of mature vascular 
endothelium. Since this initial discovery, much has been 
uncovered about the function and classification of EPCs. In 
this review, we discuss the current nomenclature, history of 
various sub-populations, EPCs isolated from both umbilical 
cord blood and placenta, and the association of EPCs with 
adverse pregnancy outcomes.
Isolation of an EPC population was first performed by Asahara 
and colleagues (9). However, the identification method used to 
isolate these cells did not include a unique identifier specific to 
EPCs. As such, many groups have since worked to further char-
acterize and develop a method to unequivocally identify EPCs. 
Unfortunately, a universal, indisputable approach to ascertaining 
a progenitor population has yet to be found. Progress, however, has 
been made to further characterize EPCs and EPC sub-types, and 
along the way, new nomenclature and identification techniques 
have been introduced. Differing names and techniques can be 
confusing and makes it difficult to decipher if previous reports 
are applicable to current investigation. To best understand the 
current state of the field, it is helpful to have an appreciation for 
where the field began.
The initial identification of EPCs utilized Ficoll centrifugation 
of peripheral blood to obtain a mononuclear cell population, and 
within this population, either CD34+ or Flk-1+ (also known as 
vascular endothelial growth factor receptor 2 or kinase insert 
domain receptor) cells were isolated with magnetic beads coated 
with the respective antibodies. These two antigens were individu-
ally targeted because both are expressed by hematopoietic stem 
cells prior to differentiation. Enriched cells were plated under 
various conditions. Attached CD34+ cells after 7 days of culture 
appeared spindle-like and expressed endothelial-specific mark-
ers including Ulex europaeus agglutinin-1, factor VIII, CD31, 
endothelial nitric oxide synthase, and DiI-labeled acetylated LDL. 
They also demonstrated an endothelial cell-like phenotype, with 
the ability to produce nitric oxide in response to acetylcholine 
and vascular endothelial growth factor. In vivo, these cells were 
incorporated into foci of neovascularization in a rabbit model 
of unilateral hindlimb ischemia. In total, these investigators 
concluded that PBMNCs isolated with anti-CD34 or anti-Flk-1 
were able to differentiate into endothelial cells, and this method 
of isolation and identification became the standard for assessing 
EPCs.
ePC iSOLATiON VIA CeLL CULTURe
Different cell culture methods of isolating EPCs utilize principles 
from the culture conditions as mentioned above, with each 
technique resulting in the isolation of different cell types. The 
method isolating endothelial colony-forming cells (ECFCs) is 
widely accepted as the closest representation of an EPC in vitro 
population. Isolation of ECFCs includes Ficoll centrifugation 
of PBMNCs, plating on collagen-1 coated plates, culturing in 
complete EGM-2 media (cEGM-2; Lonza) with 20% FBS, and 
expansion of colonies that appear typically between 14 and 
21 days after isolation (Figure 1). This method produces colo-
nies with cobblestone morphology indicative of an endothelial 
cell type. Functionally, these cells are able to migrate and form 
capillary-like structures, proliferate, and repopulate from a single 
cell (Figure 2) (10). These cells can sustain multiple passages in 
culture, but most experts recommend use of low passage number 
cells (P2–5) for experimental purposes. This cell type is also 
known as late outgrowth EPCs, blood outgrowth endothelial cells 
(10, 11), and can be defined as low or high proliferative potential 
(LPP and HPP, respectively) (12).
While this method is accepted, it has limitations. Currently, 
there are no studies linking ECFCs, an in  vitro population, to 
physiologic cell populations. Another issue with this method is 
the quantity of blood required to produce colonies. Estes et al. has 
recommended a minimum of 16 mL of peripheral blood for the 
isolation of ECFCs in healthy adults (13). When isolating from 
umbilical venous cord blood, which has a higher percentage of 
ECFCs than adult peripheral blood (12), a minimum of 5  mL 
is required, although 10–20  mL is recommended. However, in 
conditions where the pregnancy is affected by certain patholo-
gies, especially those resulting in preterm delivery, collecting an 
appropriate amount of cord blood can be difficult. Obtaining an 
adequate amount can also become problematic when trying to 
isolate ECFCs from infants and children.
Other cell culture isolation methods have been reported in 
the literature including colony-forming unit-endothelial cells 
(CFU-ECs) (14) and CFU-Hill (15) and early outgrowth EPC. 
A description of the nomenclature, isolation method, and limita-
tions are outlined in Table 1. All of these names refer to similar 
cells, in that they have a spindle-like morphology, do not incor-
porate into vessels in vivo, and are likely of myeloid or lymphoid 
progenitor background (10, 16, 17).
ePC iSOLATiON VIA FLOw CYTOMeTRY
Another commonly used method for identifying EPCs is flow 
cytometry, and similar to cell culture methods of isolation, 
there are many differing sets of antigens used. The most recent 
FiGURe 1 | isolation of endothelial colony-forming cell schematic. The diagram depicts peripheral blood mononuclear cell separation via a Ficoll gradient, 
plating on collagen, and the appearance of colonies with cobblestone morphology.
FiGURe 2 | Assessment of endothelial colony-forming cell (eCFC) function. (A) Representative image of a tube formation assay, where ECFCs are capable 
of forming capillary-like structures with the formation of branches and closed loops. (B) A classic wound migration demonstrates that ECFCs are able to migrate and 
close the wound. (C) ECFC proliferation is shown with BrdU staining in green (DAPI in blue). (D) Single-cell assay shows that ECFCs are capable of repopulation 
from a single cell.
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FiGURe 3 | Circulating progenitor cell (CPC) flow cytometry gating strategy adapted from Gumina et al. (23). Here, peripheral blood mononuclear cells 
were analyzed by polychromatic flow cytometry. Live mononuclear cells were selected and then gated for CD14− and glycophorin A− cells to exclude erythrocytes 
and macrophages. Next, the CD45dim and CD34+ population was selected from which the pro-angiogenic (CD45dim CD34+ CD31+ AC133+) and non-angiogenic 
(CD45dim CD34+ CD31+ AC133−) CPCs were identified.
TABLe 1 | The most commonly used nomenclature, isolation method, and associated identification markers of endothelial progenitor cells (ePCs) 
in vitro.
Cell culture models
Name Other names isolation method identifying markers Reference
Endothelial 
colony-forming 
cells
Blood outgrowth 
endothelial cells
Late outgrowth 
EPCs
Peripheral blood mononuclear cells (PBMNCs) are isolated 
from peripheral blood with a Ficoll gradient. Cells are plated 
on collagen-1, grown in cEGM-2, and colonies appear 
between 14 and 21 days in culture
Expression of CD31; CD141; CD105; CD146; CD144; 
vWF; Flk-1; CD34; CD133; CD117; eNOS
(12, 18)
Negative staining for CD45, CD14
Single-cell assay: able to repopulate from a single cell
Able to form capillary structures in vitro
Cobblestone morphology
Colony-forming 
unit-endothelial 
cells
Early outgrowth 
EPCs, CFU-Hill 
EPCs
PBMNCs are isolated from peripheral blood similar to 
above, plated on fibronectin, grown in M199 medium, and 
colonies appear between 5 and 7 days in culture
Expression of CD34, vWF, CD144, Flk-1, UEA-1, Tie-2 (10, 14, 19)
DiI-Ac-LDL uptake
Negative staining for VCAM-1
Spindle-like morphology
vWF, von Willebrand factor; Flk-1, vascular endothelial growth factor receptor-2; eNOS, endothelial nitric oxide synthase; UEA-1, Ulex europaeus agglutinin-1; VCAM-1, vascular cell 
adhesion molecule-1; Tie-2, TEK receptor tyrosine kinase; DiI-Ac-LDL, DiI-conjugated acetylated low-density lipoprotein.
4
Gumina and Su EPCs of the Human Placental and Fetoplacental Circulation
Frontiers in Pediatrics | www.frontiersin.org March 2017 | Volume 5 | Article 41
version identifies circulating progenitor cells (CPCs) and 
allows for sub-group analysis of pro-angiogenic CPCs (CD45dim 
CD34+CD31+AC133+) and non-angiogenic CPCs (CD45dim 
CD34+CD31+AC133−) (Figure  3) (13, 20). The current limita-
tions of this method include at least 1 × 106 cells for staining. This 
is not an issue when performed alone, but when paired with cell 
culture isolation, cell quantity may be inadequate. Additionally, as 
there are steps required for multiple antigen staining, these cells 
need to be fixed, and therefore it is not possible to culture these 
cells for ECFC comparison. It is important to note that ECFCs 
exist in the flow cytometry literature as well but are distinct 
from CPC populations. Specifically, ECFCs are a rare popula-
tion thought to be identifiable with the CPC staining profile but 
instead of CD45dim, they are CD45− (12, 21). Older methods using 
a combination of CD34+Flk-1+CD133+ are likely incorporating 
angiogenic macrophages (22), which confound much of the older 
literature. Table 2 provides a description of the nomenclature and 
staining protocols in the literature.
TABLe 2 | The most commonly used nomenclature and associated 
staining protocol for flow cytometry identification of endothelial 
progenitor cells (ePCs).
Flow cytometry
Name Staining protocol Reference
EPC/circulating endothelial 
precursor
CD45− and/or CD34+AC133+KDR+ (9, 24)
Circulating endothelial cell CD31brightCD34+CD45−CD133− (25)
Pro-angiogenic circulating 
progenitor cell (CPC)
CD45dimCD34+CD31+AC133+ (13, 20)
Non-angiogenic CPC CD45dimCD34+CD31+AC133− (13, 20)
Endothelial colony-forming cell CD45−CD34+CD31+AC133−CD146+ (13, 21)
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PLACeNTAL AND UMBiLiCAL CORD 
BLOOD ePCs
There has been considerable interest in alternative sources for EPCs 
beyond adult peripheral blood or bone marrow isolation. Various 
groups have demonstrated the presence of EPCs within both the 
human placenta and umbilical cord blood. Investigation of EPCs 
within the placenta has been limited, while literature surrounding 
cord blood EPCs has been much more robust. Nevertheless, a few 
different laboratories have described isolation of ECFCs from the 
human placenta, although some differences exist such as surface 
molecule expression (26–28). For example, Sölder et al. isolated 
CD45−CD34+CD133+Flk-1+ fetal endothelial cells from the pla-
centa and showed that they were able to form tubes on a Matrigel 
assay (28). By contrast, CD45−CD34−CD31+Flk-1+CD144+ cells 
were isolated by Rapp and colleagues, and these cells were able to 
form chimeric blood vessels in an in vivo vasculogenesis bioassay 
(26).
Unlike placentally derived EPCs, umbilical cord blood 
EPCs have been more extensively investigated. Earlier studies 
isolated EPCs that were characterized via early methodologies 
first described by Asahara and colleagues (9), which again, 
was the first description of a putative EPC population in adult 
peripheral blood (29, 30). Thus, these early cord blood EPCs are 
more consistent with CFU-ECs and not ECFCs. More recent 
studies of cord blood ECFCs demonstrate expression of various 
endothelial-derived surface markers (Table  1), with these cells 
exhibiting significant clonogenic and proliferative potential (12, 
31). Importantly, cord blood ECFCs are enriched and display 
enhanced clonogenic and proliferative potential in comparison 
to adult peripheral blood (12). However, adult peripheral and 
cord blood ECFCs do not show any difference in tube formation 
capability or induction of vascular cell adhesion molecule-1 with 
inflammatory stimuli (12). When compared to placental ECFCs, 
though, cord blood ECFCs form significant fewer blood vessels 
in an in vivo vasculogenesis assay (26).
UMBiLiCAL CORD BLOOD ePCs  
AND DiSeASe
In spite of the current limitations in identifying EPCs, there are 
numerous studies that have indicated reduced colony number 
and/or dysfunction of EPCs isolated from the umbilical cord 
blood of pregnancies complicated by preeclampsia, FGR, and 
gestational diabetes mellitus (GDM). In this review, we focus 
solely on studies that analyze either ECFCs in cell culture or CPCs 
derived from flow cytometry in order to avoid further confusion 
with other isolation methods that likely produce cell types inde-
pendent of EPCs. It is important to note that other literature exists 
analyzing other cell populations described in Tables 1 and 2.
With regard to preeclampsia, different groups of investigators 
have demonstrated both reductions in circulating number and 
abnormal function of ECFCs isolated from the venous cord blood 
of babies born to preeclamptic mothers (23, 32, 33). Specifically, 
Gumina et al. showed a decrease in both pro- and non-angiogenic 
subsets of CPCs identifiable by flow cytometry in pregnancies 
complicated by preeclampsia in comparison to normotensive 
controls. All three reports also indicate fewer ECFC colony num-
bers in their respective preeclamptic populations. From a func-
tional perspective, two groups reported that ECFCs from cord 
blood of preeclamptic pregnancies demonstrated diminished 
growth and migration (23, 32), while other laboratories found 
no difference in ECFC tube formation (23, 33). However, von 
Versen-Höynck et al. demonstrated a deficiency in preeclamptic 
ECFC tube formation, with partial improvement with vitamin D3 
treatment (32).
Similar findings have been demonstrated in pregnancies com-
plicated by FGR. Cord blood from FGR-complicated pregnan-
cies showed fewer CPCs and ECFCs in comparison to controls, 
although this was seen only in arterial cord blood (34). ECFCs 
from the FGR offspring also showed diminished proliferation 
and migration. Furthermore, FGR ECFCs implanted into mice 
prepared for an in  vivo vasculogenesis bioassay resulted in a 
sixfold increase in de novo capillary formation in comparison 
to controls (34). Taken together, the abnormalities seen in cord 
blood ECFCs in preeclampsia and FGR may be one mechanism 
that contributes to placental dysfunction and long-term elevated 
risks for cardiovascular disease in these offspring.
There is conflicting data regarding CPCs and ECFCs 
from the cord blood of GDM pregnancies. For example, one 
group of investigators found a decrease in CPCs and the 
CPC:non-CPC ratio in cord blood from GDM pregnancies 
in comparison to controls, but there was no difference in 
ECFCs, suggesting that endothelial function is intact at birth 
(35). By contrast, others have shown a decrease in ECFC 
colonies, proliferation, migration, and tube formation 
in cord blood of pregnancies complicated by GDM (36). 
From a mechanistic perspective, fetal ECFCs exposed to 
in  vitro hyperglycemia demonstrated impaired migration 
and diminished tube formation in comparison to those 
exposed to normoglycemic conditions (36). ECFCs from 
GDM pregnancies, however, were also found to be resistant 
to hyperglycemia-induced senescence (36, 37). In total, this 
suggests that although cord blood EPCs in GDM pregnancies 
may have undergone a phenotypic alteration that renders 
them tolerant to a hyperglycemic environment, they still 
demonstrate functional abnormalities that may contribute 
to the increased risks of cardiovascular disease in offspring 
of diabetic women.
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CURReNT LiMiTATiONS AND FUTURe 
AReAS OF iNveSTiGATiON
There are several limitations within the field that may amplify 
discrepancies between findings in different studies. First, a com-
prehensive characterization of ECFCs in relation to normal physi-
ology of the fetus and neonate is lacking. Additionally, knowledge 
of gestational age norms is also essentially non-existent, and this 
further hampers the field of investigation regarding EPCs and 
other pathogenic conditions that relate more directly to impaired 
placental vascularization, including FGR and stillbirth. Second, 
there are methodological issues that have yet to be standardized. 
For example, when ECFC number is assessed, it refers to the num-
ber of colonies that appear. ECFC colonies typically arise between 
14 and 21 days in vitro, although colonies can still develop beyond 
this time frame (33). Thus, discrepancies in the literature may be 
a result of when the colonies are counted, and this may be one 
reason why studies differ in their interpretation of how ECFCs 
are specifically impacted by each condition. Third, controversy 
also exists when assessing ECFC function. Functionality is 
most commonly evaluated by measures of proliferation, migra-
tion, and ability to form capillary-like structures. As discussed 
above, all of these cellular processes can be assayed with various 
techniques and each technique can have slight differences that 
result in differing findings. Additionally, few studies incorporate 
in vivo models such as ischemic injury animal models in which a 
Matrigel plug embedded with patient-derived ECFCs is injected 
into the area of ischemia and ECFC incorporation into newly 
formed vessels is later analyzed. This model (38, 39) would yield a 
better understanding of ECFC function in a physiological setting.
In addition to methodological issues, it is also possible that 
different study populations are being investigated. For example, 
preeclampsia can present across a wide gestational age range and 
with varying degrees of severity. However, it has been shown that 
ECFCs are enriched at different gestational ages within umbilical 
cord blood, with gestational age likely to affect findings (31). 
Furthermore, the effect of the severity of the condition itself 
on ECFCs has also not yet been explored. Because number and 
function of ECFCs has been associated with adverse neonatal 
outcomes such as moderate or severe bronchopulmonary dyspla-
sia, which itself has also been linked to severity of preeclampsia 
and FGR, it is not inconceivable that the status of the disease may 
affect ECFCs (18). As another example, ECFCs are increased 
in infants affected by chorioamnionitis, further suggesting that 
in utero environment may play a role on umbilical cord blood and 
placental EPCs (18).
Finally, in addition to continued cord blood EPC research, 
further investigation is also needed with regard to placental EPCs. 
The few existing studies utilize different isolation methods, dem-
onstrate slight differences in immunophenotype, and perhaps 
most compellingly, suggest that there might be enhanced colony 
formation and functional characteristics in comparison to umbili-
cal cord blood EPCs. As the field continues to advance, umbilical 
cord blood and placental EPCs are areas ripe with opportunity 
to better understand mechanisms underlying pregnancy-related 
diseases and adverse perinatal outcome. Continued investigation 
may yield preventative treatments or interventions for these preg-
nancy and perinatal complications in the future. Yet, this field 
has the potential to provide treatment targets beyond perinatal 
and neonatal outcomes by further elucidating mechanisms of 
fetal programming effects that contribute to increased risks for 
disease later in life.
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